Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development
Reference number: GID-TA10606
Expected publication date: TBC
The Department for Health and Social Care has asked NICE to conduct an appraisal of obeticholic acid within its marketing authorisation for treating liver fibrosis in people with non-alcoholic steatohepatitis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.